Partial Seizures

Neurology
11
Pipeline Programs
3
Companies
6
Clinical Trials
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
4
7
Early DiscoveryClinical DevelopmentMarket

On Market (6)

Approved therapies currently available

Abbott
DEPAKOTE CPApproved
divalproex sodium
Abbott
oral1990
UP
KEPPRAApproved
levetiracetam
UCB Pharma
oral1999
UP
KEPPRA XRApproved
levetiracetam
UCB Pharma
oral2008
U
SPRITAMApproved
levetiracetam
Unknown Company
oral2015
U
ZONEGRANApproved
zonisamide
Unknown Company
Anti-epileptic Agent [EPC]oral2000
U
ZONISAMIDEApproved
zonisamide
Unknown Company
oral2005

Competitive Landscape

3 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
4 programs
2
1
Adjunctive ZonisamidePhase 41 trial
ZonisamidePhase 31 trial
ZonisamidePhase 31 trial
PerampanelN/A1 trial
Active Trials
NCT04257604Completed243Est. Apr 2019
NCT00327717Completed240Est. May 2008
NCT01136954Completed144Est. Mar 2012
+1 more trials
Abbott
AbbottABBOTT PARK, IL
1 program
1
1
Divalproex SodiumPhase 31 trial
Active Trials
NCT00102713Completed50
UP
UCB PharmaBelgium - Brussels
1 program
1
1
LevetiracetamPhase 31 trial
Active Trials
NCT03340064Completed38Est. Jul 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiAdjunctive Zonisamide
UCB PharmaLevetiracetam
EisaiZonisamide
EisaiZonisamide
AbbottDivalproex Sodium
EisaiPerampanel

Clinical Trials (6)

Total enrollment: 915 patients across 6 trials

NCT01630057EisaiAdjunctive Zonisamide

Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug

Start: Sep 2009Est. completion: Jul 2012200 patients
Phase 4Completed
NCT03340064UCB PharmaLevetiracetam

A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age

Start: Nov 2017Est. completion: Jul 202338 patients
Phase 3Completed
NCT01136954EisaiZonisamide

A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)

Start: Jul 2008Est. completion: Mar 2012144 patients
Phase 3Completed
NCT00327717EisaiZonisamide

Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures

Start: Sep 2006Est. completion: May 2008240 patients
Phase 3Completed
NCT00102713AbbottDivalproex Sodium

A Study for Treatment of Partial Seizures in Children

Start: Feb 200550 patients
Phase 3Completed
NCT04257604EisaiPerampanel

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Start: Jan 2016Est. completion: Apr 2019243 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
12h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
12h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
13h ago

Director of Finance

CoMind
London, UK
13h ago

Electronics Engineering Manager

CoMind
London, UK
13h ago

Director of Information Technology

Zavation Medical Products
13h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space

Related Indications

Epilepsy(296)Multiple Sclerosis(283)Schizophrenia(268)Parkinson Disease(185)Alzheimer's Disease(179)Parkinson's Disease(163)Alzheimer Disease(119)Stroke(102)Depression(84)Relapsing-Remitting Multiple Sclerosis(84)